First Human Death Linked to Rare Shamonda Virus Highlights Emerging Zoonotic Threat

A 60‑year‑old French man with leukemia has become the first confirmed human victim of the rare Shamonda virus, dying on 9 October after a 16‑day battle with severe neurological complications. The case, detailed in a recent Eurosurveillance report, marks the first known spill‑over of this orthobunyavirus from livestock to a person and raises urgent questions about emerging zoonotic threats. The patient, a resident of the rural Rhône‑Alpes region, first exhibited vision loss and confusion in early October. Within days he suffered seizures, slipped into a coma, and required intubation and mechanical ventilation. Despite aggressive therapy—including broad‑spectrum antibiotics, an antiviral agent, and high‑dose corticosteroids—his condition deteriorated, leading clinicians to withdraw life support. Shamonda virus belongs to the family orthobunyaviruses, a group of arthropod‑borne pathogens that primarily infect cattle, deer and other ungulates. Transmission is usually mediated by mosquitoes and midges. “The most plausible route of infection was a bite from an infected midge,” wrote the authors, noting that food‑borne or transfusion pathways are considered unlikely. Krispin Hajkowicz of the University of Queensland emphasized that no vaccines or specific antivirals exist for orthobunyaviruses. The incident arrives against a backdrop of increasing orthobunyavirus detections in humans, a trend attributed to climate change, expanding wildlife‑livestock‑human interfaces, and a growing population of immunocompromised individuals. Daniel Rawle of QIMR Berghofer highlighted that while human‑to‑human spread has not been documented for most orthobunyaviruses, the 2024 Oropouche outbreak in Brazil did record mother‑to‑fetus transmission. Public‑health experts now call for intensified surveillance of livestock, vector control, and research into diagnostics and therapeutics. The French case underscores how a virus once confined to cattle can become lethal when it breaches species barriers, especially in vulnerable patients.